Abstract
The status of CDKN2a gene, coding for p16 and p19ARF proteins, was examined in 55 colorectal cancers. Polymerase chain reaction (PCR), single stranded conformational polymorphism and sequencing revealed 1 case of CDKN2a mutation. Methylation-specific PCR detected p16 locus methylation in 37 (73%) of 51 normal samples and 29 (53%) of 55 cancers (P=0.035). p16 transcript absence (assessed by reverse transcription-polymerase chain reaction) was noted in 10 (45%) of 22 normal samples and four (14%) of 29 cancers (P=0.012) and correlated with gene methylation (P=0.036). The decreasing frequency of p16 silencing in cancer comparing to normal mucosa does not support the postulated role of p16 in colorectal carcinogenesis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Carrier Proteins / genetics
-
Cell Cycle Proteins*
-
Colon / metabolism
-
Colon / pathology
-
Colorectal Neoplasms / genetics*
-
Colorectal Neoplasms / pathology
-
Cyclin-Dependent Kinase Inhibitor p15
-
Cyclin-Dependent Kinase Inhibitor p16 / genetics*
-
DNA / chemistry
-
DNA / genetics
-
DNA / metabolism
-
DNA Methylation*
-
Gene Expression Regulation
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Intestinal Mucosa / metabolism*
-
Mutation
-
Promoter Regions, Genetic
-
Proteins / genetics
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Tumor Suppressor Protein p14ARF
-
Tumor Suppressor Proteins*
Substances
-
CDKN2B protein, human
-
Carrier Proteins
-
Cell Cycle Proteins
-
Cyclin-Dependent Kinase Inhibitor p15
-
Cyclin-Dependent Kinase Inhibitor p16
-
Proteins
-
RNA, Messenger
-
Tumor Suppressor Protein p14ARF
-
Tumor Suppressor Proteins
-
DNA